[go: up one dir, main page]

CL2015002971A1 - Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited. - Google Patents

Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited.

Info

Publication number
CL2015002971A1
CL2015002971A1 CL2015002971A CL2015002971A CL2015002971A1 CL 2015002971 A1 CL2015002971 A1 CL 2015002971A1 CL 2015002971 A CL2015002971 A CL 2015002971A CL 2015002971 A CL2015002971 A CL 2015002971A CL 2015002971 A1 CL2015002971 A1 CL 2015002971A1
Authority
CL
Chile
Prior art keywords
capacity
biopharmacological
msc
secreted
tissue
Prior art date
Application number
CL2015002971A
Other languages
Spanish (es)
Inventor
Marcelo Ezquer Eduardo
Fernando Ezquer Eduardo
Original Assignee
Univ Del Desarrollo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Del Desarrollo filed Critical Univ Del Desarrollo
Priority to CL2015002971A priority Critical patent/CL2015002971A1/en
Publication of CL2015002971A1 publication Critical patent/CL2015002971A1/en
Priority to PCT/CL2016/050052 priority patent/WO2017059555A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención corresponde a una composición biofarmacológica que comprende componentes producidos y/o secretados por células troncales mesenquimales (MSC), preferentemente humanas, que permite recuperar la capacidad regenerativa tisular, en una situación de esteatosis hepática.The invention corresponds to a biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (MSC), preferably human, which allows recovering the regenerative tissue capacity, in a situation of hepatic steatosis.

CL2015002971A 2015-10-05 2015-10-05 Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited. CL2015002971A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2015002971A CL2015002971A1 (en) 2015-10-05 2015-10-05 Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited.
PCT/CL2016/050052 WO2017059555A1 (en) 2015-10-05 2016-10-03 Biopharmacological composition comprising components produced and/or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity in a situation of hepatosteatosis or when the endogenous regenerative capacity of hepatic tissue is inhibited

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2015002971A CL2015002971A1 (en) 2015-10-05 2015-10-05 Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited.

Publications (1)

Publication Number Publication Date
CL2015002971A1 true CL2015002971A1 (en) 2016-06-24

Family

ID=56610077

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002971A CL2015002971A1 (en) 2015-10-05 2015-10-05 Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited.

Country Status (2)

Country Link
CL (1) CL2015002971A1 (en)
WO (1) WO2017059555A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018236194A1 (en) * 2017-06-23 2018-12-27 이화여자대학교 산학협력단 Composition for prevention or treatment of fibrosis, comprising gas6 protein or receptor activator thereof
CN110156887B (en) * 2018-02-12 2023-01-13 中国人民解放军军事科学院军事医学研究院 Human VASN protein antigen epitope, antigen mimic epitope and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2759228T3 (en) * 2013-07-05 2020-05-08 Univ Catholique Louvain Conditioned medium for adult liver stem cells and their use in the treatment of liver disorders

Also Published As

Publication number Publication date
WO2017059555A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
MX2019014009A (en) Improved methods for manufacturing adoptive cell therapies.
ECSP17039547A (en) NEW STANDARDS AND MEDICAL DEVICES FOR THE PREPARATION OF PLASMA RICH IN PLATES (PRP) OR BONE MARROW CONCENTRATE (BMC) ALONE OR COMBINED WITH HYALURONIC ACID
BR112017017886A2 (en) generating arterial endothelial cell populations
MX2018001531A (en) Taurine supplemented cell culture medium and methods of use.
AR094583A1 (en) COMPOSITIONS INCLUDING AGENTS TO CONFER HYDROPHOBIC AND STABILIZING CHARACTER AND METHODS TO PREPARE AND USE THE SAME
MX2016014129A (en) COMPOSITIONS FOR THE CONTROL OF MOSQUITOS AND USES OF THE SAME.
MX390739B (en) COMPOSITION OF COMPRESSED BONE AND METHOD OF USING SAME.
MX390493B (en) Compositions comprising mesenchymal stem cells and uses thereof
MX377300B (en) STEM CELL THERAPY IN ENDOMETRIAL PATHOLOGIES.
MX2017016345A (en) FUSION PROTEINS TO INHIBIT ANGIOGENESIS.
CL2019000640A1 (en) Dengue virus antibodies, polypeptides containing variant fc regions, and methods of use.
CO2018000350A2 (en) Crystalline form of monohydrated plinabulin, compositions comprising it and manufacturing procedures
BR112016030758B8 (en) USE OF MULTIPOTENT STROME CELLS DERIVED FROM MESENCHYMAL ADIPOSE TISSUE
MX2017014336A (en) Low density carbon fibers filled materials.
LT3250202T (en) COMPOSITION FOR USE TO IMPROVE HEMATOGRAPHIC STEM CELLS AFTER TRANSPLANTATION
BR112017009289A2 (en) methods of administering amantadine compositions
ECSP16058769A (en) COMPOSITION FOR THE ORAL ADMINISTRATION OF BIOACTIVE AGENTS
MX2020004063A (en) Systems and methods to produce b cells genetically modified to express selected antibodies.
EA201790415A1 (en) LYOPHYLIZED COMPOSITIONS FOR THE ANTIDOT OF FACTOR Xa
MX2019001257A (en) Bioactive renal cells for the treatment of chronic kidney disease.
EA201692518A2 (en) METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS AFTER FONTENE OPERATION USING UDENAFIL COMPOSITIONS
MX373950B (en) USE OF A TEMPORARY INHIBITOR OF A p53 GENE FOR PROPHYLAXIS OF ISCHEMIA-REPERFUSION INJURY.
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
CL2015002971A1 (en) Biopharmacological composition comprising components produced and / or secreted by mesenchymal stem cells (msc), which allows the recovery of tissue regenerative capacity, in a situation of hepatic steatosis, or where the endogenous regeneration capacity of liver tissue is inhibited.
DK3197431T3 (en) FOAMING COMPOSITIONS AND METHODS FOR DELIVERING AN ACTIVE AGENT TO A BODY CAVITY